FKONCO

Fresenius Kabi Oncology Limited has informed the Exchange regarding a press release dated May 26, 2011 , titled " FRESENIUS KABI ONCOLOGY LIMITED TO FOCUS ON CONTRACT R & D AND MANUFACTURING ACTIVITIES."

Fresenius Kabi Oncology Limited has informed the Exchange that "Fresenius Kabi Oncology Ltd. has renewed the tenure of Memorandum of Understanding entered into with our RTA (MCS Ltd) on January 12, 2004 for a further period of one year from January 12, 2010 to January 11, 2011 on the existing terms and conditions."

Fresenius Kabi Oncology Limited has informed the Exchange that in the meeting of the Board of Directors of the Company held on July 30, 2009, the following matter has been considered and approved: Further expansion of plant at D-35, Industrial Area, Kalyani, District Nadia, West Bengal 741 235, with an estimated cost of INR 230 million.

Dabur Pharma Limited has informed the Exchange that in the meeting of the Board of Directors of the Company, held on January 29, 2009, the following matters have been considered and approved: 1) Shifting of Registered Office of the Company from "3, Factory Road, Adj. Safdarjung Hospital, New Delhi - 110 029" to "B - 310, Som Datt Chambers - I, Bhikaji Cama Place, New Delhi - 110 066" w.e.f. January 29, 2009. 2) Expansion of plant at D - 35, Industrial Area, Kalyani, District Nadia, West Bengal 741 235, with an estimated cost of Rs. 72.4 crores.

Dabur Pharma Limited has informed the Exchange regarding a press release dated October 23, 2008, titled "Dabur Pharma Declares Financial Results". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/DABUR_PR_24102008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed regarding a press release dated July 31, 2008, titled "Dabur Pharma Declares Financial Results: Registers 11.7% Growth". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Daburpharma_PR_31072008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange regarding a press release dated May 30, 2008, titled "Dabur Pharma announces results for fiscal 2007-08". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/daburpharma_pr_30052008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange regarding a press release dated May 21, 2008, titled "Dabur Pharma receives USFDA approval for Generic Mitoxantrone". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Dabur_PR_21052008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange that: "The new unit of the Company situated at Kishanpura, Distt. Solan, Himachal Pradesh has commenced its commercial production."

Dabur Pharma Limited has informed the Exchange regarding a press release dated April 21, 2008, titled "Burmans' of the Dabur Group unlock significant value from Dabur Pharma". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Daburpharma_PR_21042008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange that: "The promoters and certain other shareholders of Dabur Pharma Limited ("Company'') have executed share purchase agreements with Fresenius Kabi (Singapore) Pte Ltd ("Fresenius") pursuant to which Fresenius will acquire approximately 73.27% of the total issued and paid-up equity share capital of the Company at Rs.76.50 per equity share, subject to fulfillment of certain conditions precedent including receipt of necessary regulatory approvals and the compliance by Fresenius with public offer requirements under the SEBI (Substantial Acquisition

Dabur Pharma Limited has informed the Exchange regarding a press release dated April 09, 2008, titled "Dabur Pharma Signs Agreement with Government Pharmaceutical Organization, Thailand for Cost effective Anticancer Product". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/DaburPharma_PR_09042008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange regarding a press release dated March 11, 2008, titled "Irinotecan Gets Approval in Italy & Denmark". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/DaburPharma_PR_11032008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange regarding a press release dated February 28, 2008, titled "Dabur Pharma Announces Approval & Launch of Irinotecan Hydrochloride Injection in United States". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). <a href=/content/corporate/DaburPharma_PR_29022008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange regarding a press release dated January 30, 2008, titled "Dabur Pharma's Nanoxel Receives DCGI Approval for Additional Indications". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/daburph_PR_31012008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange regarding a press release dated January 30, 2008, with respect to Unaudited Financial results for the third Quarter ended December 31, 2007. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Daburpharma_PR_30012008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange regarding a press release dated October 30, 2007, titled "Dabur Pharma Receives USFDA Approval For Generic Irinotecan". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements)<a href=/content/corporate/Daburpharma_PR_30102007.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange regarding a press release with respect to its unaudited financial results for the quarter ended September 30, 2007. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements)<a href=/content/corporate/Daburpharma_PR_26102007.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange regarding a press release dated July 26, 2007, titled "Dabur Pharma Reports Excellent Financial Results for First Quarter FY'08." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/dabur_PR_260707.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange regarding a press release dated January 23,2007, titled "Dabur Pharma reports Excellent Financial Results for quarter & nine months ended, December 31, 2006". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Daburpharma_PR_23012007.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange that the Company has acquired the entire oncology (anti-cancer) sales & distribution business from its partner Biosciences Co. Ltd. in Thailand through its wholly owned subsidiary. The copy of press release in this regard dated January 09, 2007, titled "Dabur Pharma Acquires Sales & Distribution Business in Thailand" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/dabur_press_090107.zip target=NEW> For

Dabur Pharma Limited has informed the Exchange that "the Company has launched Nanoxel- a novel drug delivery system for the widely used anti-cancer drug Paclitaxel. This nanoscale drug delivery system is India's first indigenously developed nanotechnology based chemotherapy agent. A copy of press release in this regard dated January 04, 2007, titled �Dabur Pharma introduces Nanoxel in India" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Dabur_PR_0

Dabur Pharma Limited has informed the Exchange that the company has issued a press release dated January 28, 2005 regarding the unaudited financial results of the Company for the quarter ended December 31, 2004 and also that the Company's Bulk Drug Plant at Kalyani, West Bengal, has received USFDA approval for 'Metaxalone' a muscle relaxant. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).